Epixone-SL 500mg/250mg Injection
Marketer
Epitome Life Sciences
Salt Composition
Ceftriaxone (500mg) + Sulbactam (250mg)
Overview Epixone-SL 500mg/250mg Injection
Combiflox-500 Injection, a dual-action medication, combats diverse bacterial infections. Its mechanism inhibits microbial proliferation, thus curbing infection spread. Administration must be solely under a physician's guidance. Strict adherence to the prescribed dosage schedule is crucial; completing the entire course is vital, even with symptom improvement. Premature cessation may compromise efficacy. Potential side effects include nausea, vomiting, diarrhea, and dyspepsia; intensified effects necessitate immediate medical attention. Allergic reactions (rash, pruritus, edema, dyspnea) require prompt emergency care. Inform your doctor of all concurrent medications, including those for pre-existing conditions. Expectant and lactating mothers require prior medical consultation. Alcohol consumption should be avoided due to potential additive drowsiness. While generally non-impairing to driving ability, refrain from driving if experiencing somnolence or vertigo. Adequate rest, nutritious food, and ample hydration facilitate recovery. Your physician may order tests to monitor the medicine's impact.
Uses of Epixone-SL 500mg/250mg Injection
Infections caused by bacteria
Major Benefits of Epixone-SL 500mg/250mg Injection:
Administering this medication will be handled by your physician or registered nurse; self-medication is strongly discouraged.
Common Side effects of Epixone-SL 500mg/250mg Injection:
- Increased white blood cell count (eosinophils)
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Rash
- Diarrhea
- Increased liver enzymes
- Injection site reactions (pain, swelling, redness)
How to use Epixone-SL 500mg/250mg Injection:
This medication will be administered by your healthcare provider. Self-medication is not advised.
How Epixone-SL 500mg/250mg Injection works:
Ceftriaxone/Sulbactam 500mg/250mg (Epixone-SL) injection combines the antibiotic Ceftriaxone with the beta-lactamase inhibitor Sulbactam. Ceftriaxone's antibacterial action stems from its disruption of bacterial cell wall synthesis, a crucial process for bacterial viability. Sulbactam counters bacterial resistance mechanisms, thereby augmenting Ceftriaxone's effectiveness.
SAFETY ADVICE
AlcoholSAFE
There are no known adverse interactions between Epixone-SL 500mg/250mg Injection and alcohol consumption.
PregnancySAFE IF PRESCRIBED
The injectable formulation Epixone-SL (500mg/250mg) is typically regarded as safe for use during gestation. Preclinical trials in animals revealed minimal or no harmful consequences to the fetus; nevertheless, data from human trials are scarce.
Breast feedingCAUTION
Administering Epixone-SL 500mg/250mg Injection to breastfeeding mothers requires careful consideration. Lactation should be temporarily suspended throughout the mother's treatment and until the medication is fully cleared from her system.
DrivingUNSAFE
Administering Epixone-SL 500mg/250mg Injection may induce drowsiness, visual disturbances, and dizziness. Operating a vehicle is contraindicated should these effects manifest.
KidneyCONSULT YOUR DOCTOR
Insufficient data exists regarding the administration of Epixone-SL 500mg/250mg Injection to individuals with renal impairment. Physician consultation is advised.
LiverCAUTION
The injectable medication, Epixone-SL 500mg/250mg, requires careful administration in individuals with significant hepatic impairment; dosage modification may be necessary. Physician consultation is advised. Dosage alteration for Epixone-SL 500mg/250mg Injection is not suggested for patients experiencing mild or moderate liver dysfunction.
What if you forget to take Epixone-SL 500mg/250mg Injection :
Should you forget a scheduled injection of Epixone-SL 500mg/250mg, seek immediate medical advice.
Facts to Know About Epixone-SL 500mg/250mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Anti-infective agents |
3,018 People bought this recently